Open Registry Measuring Impact of Genomic Testing on Treatment Decision After Biopsy in Newly Diagnosed Prostate Cancer Patients
| Status: | Recruiting |
|---|---|
| Conditions: | Prostate Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/13/2015 |
| Start Date: | May 2014 |
| Contact: | Kristen Rushton |
| Email: | krushton@myriad.com |
An Open Registry to Measure the Impact of Adding Genomic Testing (Prolaris®) on the Treatment Decision Following Biopsy in Newly Diagnosed Prostate Cancer Patients by Specialists
This registry is intended to measure the impact of Prolaris® testing on therapeutic
decisions when added to standard clinical-pathological parameters in men with newly
diagnosed prostate cancer.
decisions when added to standard clinical-pathological parameters in men with newly
diagnosed prostate cancer.
Inclusion Criteria:
- Newly diagnosed (≤6 months), untreated patients with histologically proven
adenocarcinoma of the prostate that have the following characteristics.
- Clinically localized (no evidence on clinical or imaging studies of advanced disease.
- No hormonal therapy including LHRH agonist or antagonist, anti-androgen, 5-alpha
reductase inhibitor, estrogens or exogenous androgens, when applicable.
- Sufficient amount of tissue remains from biopsy to perform genomic testing.
Exclusion Criteria:
- Patients with known history of hypogonadism will be excluded from the registry
We found this trial at
1
site
Univ of Washington Founded in 1861 by a private gift of 10 acres in what...
Click here to add this to my saved trials
